β-thalassemia is a genetic disorder characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to ineffective erythropoiesis and severe anemia. Patients with transfusion-dependent β-thalassemia (TDT) require regular blood transfusions to maintain adequate hemoglobin levels. Non-transfusion-dependent thalassemia (NTDT) patients manage their anemia without regular transfusions but still experience significant health complications. Iron overload is a common and severe complication in both TDT and NTDT patients due to increased intestinal iron absorption and regular transfusions. The excess iron accumulates in vital organs, including the liver, heart, and endocrine glands, causing significant morbidity and mortality. Additionally, recent research indicates that iron overload may also adversely impact mitochondrial function, further exacerbating the pathophysiology of this disease. Excessive iron accumulation in mitochondria can impair the electron transport chain, reduce adenosine tri-phosphate synthesis, and increase the generation of reactive oxygen species, resulting in elevated tissue damage and clinical complications. A review, authored by scientists at JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India, and published on April 15, 2024 in Gene Expression, explores the mechanisms of iron overload in β-thalassemia, current diagnostic and monitoring techniques, and advances in management strategies. The open-access article is titled “Exploring the Impact of Iron Overload on Mitochondrial DNA in β-Thalassemia: A Comprehensive Review.”
Mechanisms of Iron Overload
In β-thalassemia, iron overload occurs through two primary mechanisms: transfusional iron overload in TDT patients and increased gastrointestinal iron absorption in NTDT patients due to ineffective erythropoiesis and low hepcidin levels. Hepcidin, a liver-derived hormone, regulates iron homeostasis by inhibiting intestinal iron absorption and iron release from macrophages. In β-thalassemia, hepcidin levels are inappropriately low, leading to excessive iron absorption. This dysregulation results in systemic iron overload. The iron overload leads to the production of reactive oxygen species (ROS) through iron-mediated Fenton reactions, contributing to oxidative stress and tissue damage. Chronic iron overload is particularly detrimental to the liver, heart, and endocrine organs, leading to fibrosis, cardiomyopathy, and endocrine dysfunctions, respectively.
Diagnosis and Monitoring
Diagnosing iron overload involves several parameters, with serum ferritin levels being a primary indicator. Elevated serum ferritin levels, typically above 300 ng/ml in males and 150–200 ng/ml in females, signal excess iron accumulation. However, inflammation, infection, and liver disorders can affect ferritin levels, necessitating the use of additional markers such as total iron binding capacity, serum transferrin saturation, and non-transferrin-bound iron (NTBI). Magnetic resonance imaging (MRI) has replaced liver biopsy for non-invasive quantification of hepatic iron overload and can also assess iron accumulation in the heart and other organs. T2* MRI is particularly useful for evaluating cardiac iron overload and guiding chelation therapy adjustments. Liver iron concentration (LIC) measurement through R2 and R2* MRI techniques provides a reliable assessment of hepatic iron burden.
Management Strategies
The primary treatment for iron overload is chelation therapy, which involves the use of agents such as deferoxamine, deferiprone, and deferasirox to bind excess iron and facilitate its excretion. Chelation therapy’s efficacy depends on patient adherence, which can be affected by side effects and cost. Deferoxamine, administered via subcutaneous or intravenous infusion, is effective but burdensome for patients. Oral chelators such as deferiprone and deferasirox offer more convenience, improving compliance. Emerging therapies aim to enhance chelation efficiency and reduce side effects. These include the development of new chelators, combination therapies, and the use of plant extract derivatives with antioxidant properties. Combination therapy, using deferiprone and deferoxamine, has shown synergistic effects, improving iron removal and reducing toxicity. However, cases involving mtDNA mutations introduce additional complexities, necessitating personalized treatment approaches.
Future Perspectives
Research is focused on understanding the molecular mechanisms underlying iron overload and developing targeted therapies. Advances in genetic and molecular screening have improved our understanding of genotype-phenotype correlations in thalassemia. Techniques such as next-generation sequencing (NGS) enable the identification of mutations in genes regulating iron metabolism. Innovations in gene editing, such as CRISPR-Cas9, hold promise for correcting genetic defects responsible for iron overload. Additionally, nanoparticle-based delivery systems offer potential for targeted therapy, reducing systemic toxicity, and improving therapeutic outcomes. Hepcidin mimetics and modulators are also being investigated to restore hepcidin levels and regulate iron absorption effectively.
Conclusions
Iron overload remains a significant challenge in the management of β-thalassemia. Early diagnosis and regular monitoring are crucial for preventing organ damage. While chelation therapy is the cornerstone of treatment, its limitations necessitate the exploration of novel therapeutic strategies. Advances in molecular genetics and targeted therapies offer hope for more effective management of iron overload in β-thalassemia patients. Personalized treatment approaches, informed by genetic and molecular profiling, are essential for optimizing patient outcomes. Continued research and clinical trials are vital to developing safer, more effective treatments and improving the quality of life for β-thalassemia patients worldwide.
In their conclusion, the authors write: “Iron overload is a pervasive complication in thalassemia syndrome, resulting from repeated transfusions in TDT and excessive iron absorption accompanied by suppressed hepcidin levels in NTDT patients. With limited mechanisms to eliminate excess iron from the body, iron accumulates in secondary sites such as the liver, heart, and cardiac muscles. While the clinical presentations of TDT and NTDT patients may differ in terms of the site of iron accumulation and associated organ dysfunction, the core molecular mechanism remains consistent, with ROS-induced tissue damage. Regular monitoring of blood intake, along with iron overload biomarkers such as serum ferritin levels, liver iron concentration, and advanced imaging techniques to assess iron tissue deposition, provides a crucial avenue for early detection and timely initiation of iron chelation therapy.”
“Next-generation sequencing technologies offer hope by enabling direct sequencing of mtDNA and detecting disease-causing gene variants responsible for ROS-mediated mutant lesions on mtDNA. This breakthrough has the potential to revolutionize the diagnosis and management of mitochondrial disorders in thalassemia patients. Despite the integration of iron chelation therapy alongside blood transfusions, its efficacy depends on the patient’s adherence and compliance with the chelating agent. Side effects and the cost of the chelation therapy limit adherence, and eventually result in iron overload. The prospect of replacing conventional iron chelators with novel siRNAs targeting hepcidin suppressors and tissue iron transporters holds promise for reducing excess free iron levels in tissue with limited side effects. However, a lack of clinical trials limits the practical applications of this technology. Future developments in targeted therapy must address the route of administration and optimal siRNA dosages.”
“Personalized therapy is emerging as a central focus, recognizing that each patient exhibits unique responses to therapeutic agents. Current research trends are harnessing advanced gene editing techniques, such as site-specific recombinases and CRISPR-Cas9, to mitigate mtDNA mutations despite the existence of mtDNA heteroplasmy. The future landscape holds the promise of expanded genetic screening, paving the way for novel therapeutic approaches to editing mtDNA variations, mitigating ROS-induced tissue damage, and alleviating the burdens of iron overload in individuals with β-thalassemia. As research and clinical trials progress, personalized and highly effective treatments for thalassemia-related iron overload and associated mitochondrial disorders are needed, as these treatments are expected to improve patient outcomes and quality of life.”